Neuland Laboratories Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/fgee4zg0df734aa0pg7tzw4y.pdf

Key Takeaways


CMS: The Growth Engine and Its Lumpiness

Saharsh Davuluri: "Building exclusive relationships, especially as you start working with larger pharma companies, is not something of a likely scenario because of business continuity management practices."

Working Capital: The Quarter's Real Drag


GDS: Prime Products Step Up, Specialty Stays Lumpy


Development Pipeline and Revenue Dynamics


Peptide Facility: A Capacity Option, Not a Commitment


Margins: The 30% Question

Saharsh Davuluri: "I think this quarter, what we have seen, 30% EBITDA margin, I think is representative of the nature of the business. Whether it is going to be sustainable or not is something that we may not be able to comment directly."

Guidance & Commitments

CommitmentSpecificsTimeline
Inventory optimizationBring inventory to a natural flow from the current ~₹155-160 cr build-upNext five months
Receivables smoothingEven out receivables through steps already startedBy end of March
Third molecule (CNS) commercial shipmentStart shipping a CNS productNext month or two
Long-awaited molecule commercializationStart commercial shipmentsSoon this year
Peptide Module-1 operationalModule-1 ready and operationalNext financial year
Project pipeline increaseIncrease in number of projects across tablesNext 12-18 months
New business deliveriesNew business expectedNext 12-18 months
GDS growthOptimistic about growth, but will pan out slowlyIf not this FY, next FY

Key Metrics

MetricQ2 FY26
Total income₹516 crores, +63.7% YoY vs ₹315 crores in Q2 FY25
EBITDA₹156.9 crores, margin of 30.4%
Gross margin60.1%, vs 56.3% in Q2 FY25
Profit after tax₹96.5 crores, vs ₹32 crores in Q2 FY25
EPS₹75.18 per share
Working capital155 days of sales
Free cash flownegative ₹141 crores for the quarter
Net debtnegative ₹6.6 crores
CAPEX₹91 crores for the quarter, ₹170.7 crores for H1
R&D scientist headcount385, up from 360
CMS pipeline: new commercialization expected1 molecule, shipments expected to start in the next month or two, a CNS product
CMS pipeline: commercial visibility next 12-18 monthsNo concrete visibility beyond the one molecule nearing commercialization
Peptide facility investment (Module-1 plus civil for Module-2)₹250-280 crores ballpark
Inventory increase (April to September)₹155-160 crores rise